Showing results (261-270 of 313,141) with videos related to
Sort By:
Pageof 31,315
Acta Neurochirurgica|December 31, 2014
5-ALA-induced fluorescence behavior of reactive tissue changes following glioblastoma treatment with radiation and chemotherapyMarcel A Kamp, Jörg Felsberg, Hosai Sadat, et al.Journal of Neuro-Oncology|October 21, 2009
Primary CNS lymphoma in the elderly: temozolomide therapy and MGMT statusDelia Kurzwelly, Martin Glas, Patrick Roth, et al.Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology|August 28, 2009
Neurotransmitter receptor imbalances in motor cortex and basal ganglia in hepatic encephalopathyNicola Palomero-Gallagher, Hans-Jürgen Bidmon, Markus Cremer, et al.Cancer Research|August 17, 2005
Integrative genomic analysis identifies NDRG2 as a candidate tumor suppressor gene frequently inactivated in clinically aggressive meningiomaEriks A Lusis, Mark A Watson, Michael R Chicoine, et al.Glycoconjugate Journal|June 1, 1996
In vivo growth conditions suppress the expression of ganglioside GM2 and favour that of lacto series gangliosides in the human glioma D-54MG cell lineP Fredman, C J Wikstrand, J E Månsson, et al.BMC Cancer|December 19, 2009
ECRG4 is a candidate tumor suppressor gene frequently hypermethylated in colorectal carcinoma and gliomaSilke Götze, Valeska Feldhaus, Thilo Traska, et al.The British Journal of Dermatology|April 24, 1999
Multiple basal cell carcinomas associated with hairy cell leukaemiaM P Schön, J Reifenberger, S Von Schmiedeberg, et al.International Journal of Cancer|January 9, 2001
Local immunotherapy of glioma patients with a combination of 2 bispecific antibody fragments and resting autologous lymphocytes: evidence for in situ t-cell activation and therapeutic efficacyG Jung, M Brandl, W Eisner, et al.Cancer Science|December 15, 2010
Expression of nuclear receptor corepressors and class I histone deacetylases in astrocytic gliomasBenito Campos, Justo Lorenzo Bermejo, Lin Han, et al.Neuro-Oncology|October 26, 2012
Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practiceMichael Weller, Roger Stupp, Monika E Hegi, et al.Pageof 31,315